Gonal-f

See also: Generic Gonal-f RFF, Generic Gonal-f RFF Pen

Gonal-f is a brand name of follicle stimulating hormone, approved by the FDA in the following formulation(s):

GONAL-F (follitropin alfa/beta - injectable; subcutaneous)

• 
  Manufacturer: EMD SERONO
  
  Approval date: February 28, 2001
  
  Strength(s): 1,050 IU/VIAL
  


• 
  Manufacturer: EMD SERONO
  
  Approval date: March 26, 2004
  
  Strength(s): 450 IU/VIAL ^[RLD]

Has a generic version of Gonal-f been approved?

No. There is currently no therapeutically equivalent version of Gonal-f available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gonal-f. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Follicle stimulating hormone and pharmaceutical compositions containing same
  Patent 5,767,067
  Issued: June 16, 1998
  Inventor(s): Arpaia; Guiseppe & Serani; Serenella & Sirna; Antonino & Villa; Stefano
  Assignee(s): Istituto di Ricerca Cesare Serono S.p.A.
  Purification of human FSH from post-menopausal urine gonadogropin using immunochromatography and reverse phase HPLC steps yelds a biologically active hormone which is free from detectable traces of LH and other urinary proteins.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
  Patent 5,767,251
  Issued: June 16, 1998
  Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
  Assignee(s): Genzyme Corporation
  Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  FSH and FSH variant formulations, products and methods
  Patent 7,563,763
  Issued: July 21, 2009
  Inventor(s): Hoffmann; James Arthur & Lu; Jirong
  Assignee(s): Ares Trading S.A.
  This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
  
  Patent expiration dates:
  
  
  • August 23, 2019
    
    ✓ 
    Drug product
  
  

See also...

• Gonal-f Powder Consumer Information (Wolters Kluwer)
• Gonal-F Consumer Information (Cerner Multum)
• Gonal-F Advanced Consumer Information (Micromedex)
• Follitropin Alfa Powder Consumer Information (Wolters Kluwer)
• Follitropin Alfa Solution Consumer Information (Wolters Kluwer)
• Follitropin Beta Consumer Information (Wolters Kluwer)
• Follicle stimulating hormone Consumer Information (Cerner Multum)
• Follitropin alfa Subcutaneous Advanced Consumer Information (Micromedex)
• Follitropin beta Subcutaneous Advanced Consumer Information (Micromedex)